Compare Crispr Therapeutics AG (CRSP) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while T-Rex 2X Long MSTR Daily Target ETF trades at $39.7 (market cap $809.00M). The key difference: Crispr Therapeutics AG is far larger — about 6× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| CRSP | MSTU | |
|---|---|---|
Market Cap | $4.88B | $809.00M |
Volume | 2,861,747 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $73.97 | $432.00 |
52-Week Low | $44.34 | $14.60 |
Typical Hold Time | 77 Days | 18 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
MSTU is trading at $38.33, down 2.84% on the day, with a bearish technical outlook as moving averages signal selling pressure. The stock recently underwent a 10:1 reverse stock split effective August 24, 2026, and declared a $0.29 dividend payable August 26, 2026. Key support levels are at $37 and $35, while resistance sits at $40 and $41.
The outlook remains cautious due to the bearish technical setup and lack of current fundamental data. Investment opportunities hinge on the company's ability to demonstrate improved financial performance post-reverse split, while risks include continued technical weakness and potential volatility from the leveraged ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
